Sen. Grassley seeks transparency in FDA review of heart health risks with diabetes drug
WASHINGTON --- Sen. Chuck Grassley has asked the Food and Drug Administration to respond to accounts that an agency-convened drug safety oversight board voted earlier this month to keep Avandia on the market by a one-vote margin amid agency considerations of a second warning for the drug label about heart attack risks.
Grassley said sources indicate the board vote occurred on October 2, so he’s also asking the FDA about the terms and conditions governing public notification with this sort of information.
The FDA first issued a heightened warning about Avandia and heart failure risk in August, following a May study that appeared in the New England Journal of Medicine regarding the drug’s cardiovascular risks.
“The Avandia case continues to present new rounds of questions about the way the FDA monitors and assesses drug risks and decides whether to let the public know about emerging risks,” Grassley said.
Next Article Previous Article
- Wyden Praises Confirmation of Jayme White as Deputy U.S. Trade Representative, Lily Batchelder as Assistant Secretary of Treasury for Tax Policy
- Wyden Statement on Senate Floor on Vote to Confirm Jayme White as Deputy USTR
- Wyden Statement on Senate Floor on Vote to Confirm Lily Batchelder to be Assistant Treasury Secretary for Tax Policy
- Wyden, Crapo Solicit Policy Proposals to Address Unmet Mental Health Needs
- Wyden Statement at Finance Committee Hearing on the Nominations of Christi Grimm to HHS and Neil MacBride to Treasury